Galapagos reports first quarter 2024 financial results
Advanced potentially best-in-class cell therapy and small molecule R&D pipeline comprising four clinical assets and >15 discovery programs in oncology and immunology Executed agreements with BridGene Biosciences and Thermo Fisher Scientific, and …